Treatment options for central nervous system lymphomas in immunocompetent patients

References

• Batchelor T, Loeffler JS. Primary CNS lymphoma. J. Clin. Oncol.24(8), 1281–1288 (2006).
   PubMed Web of Science ®Google Scholar
• Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet361(9354), 323–331 (2003).
   PubMed Web of Science ®Google Scholar
• Coté TR, Manns A, Hardy CR, Yellin FJ, Hartge P. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. J. Natl Cancer Inst.88(10), 675–679 (1996).
   PubMed Web of Science ®Google Scholar
• Eby NL, Grufferman S, Flannelly CM, Schold SC Jr, Vogel FS, Burger PC. Increasing incidence of primary brain lymphoma in the U.S. Cancer.62(11), 2641–2665 (1988).
   Web of Science ®Google Scholar
• Kadan-Lottick NS, Skluzacek MC, Gurney JG. Decreasing incidence rates of primary central nervous system lymphoma. Cancer95(1), 193–202 (2002).
   PubMed Web of Science ®Google Scholar
• Hochberg FH, Miller DC. Primary central nervous system lymphoma. J. Neurosurg.68(6), 835–853 (1988).
   PubMed Web of Science ®Google Scholar
• Levy-Clarke GA, Chan CC, Nussenblatt RB. Diagnosis and management of primary intraocular lymphoma. Hematol. Oncol. Clin. North Am.19(4), 739–749 (2005).
   PubMed Web of Science ®Google Scholar
• Freeman LN, Schachat AP, Knox DL, Michels RG, Green WR. Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma. Ophthalmology94(12), 1631–1639 (1987).
   PubMed Web of Science ®Google Scholar
• Whitcup SM, de Smet MD, Rubin BI et al. Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology100(9), 1399–1406 (1993).
   PubMed Web of Science ®Google Scholar
• Akpek EK, Ahmed I, Hochberg FH et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology106(9), 1805–1810 (1999).
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France (2001).
   Google Scholar
• Chan CC, Shen DF, Whitcup SM, Nussenblatt RB. Detection of human herpesvirus-8 and Epstein–Barr virus DNA in primary intraocular lymphomas. Blood93(8), 2749–2751 (1999).
   PubMed Web of Science ®Google Scholar
• Tuaillon N, Chan CC. Molecular analysis of primary central nervous system and primary intraocular lymphomas. Curr. Mol. Med.1(2), 259–272 (2001).
   PubMedGoogle Scholar
• Chan CC, Buggage RR, Nussenblatt RB. Intraocular lymphoma. Curr. Opin. Ophthalmol.13(6), 411–418 (2002).
   PubMedGoogle Scholar
• Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood101(3), 815–821 (2003).
   PubMed Web of Science ®Google Scholar
• Chan CC, Shen D, Hackett JJ, Buggage RR, Tuaillon N. Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma. Ophthalmology110(2), 421–426 (2003).
   PubMed Web of Science ®Google Scholar
• Jahnke K, Coupland SE, Na IK et al. Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma. Blood106(1), 384–385 (2005).
   PubMed Web of Science ®Google Scholar
• Abrey LE, Batchelor TT, Ferreri AJ et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J. Clin. Oncol.23(22), 5034–5043 (2005).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Blay JY, Reni M et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma study group experience. J. Clin. Oncol.21(2), 266–272 (2003).
   PubMed Web of Science ®Google Scholar
• Abrey LE, Ben-Porat L, Panageas KS et al. Primary central nervous system lymphoma: the Memorial Sloan–Kettering Cancer Center prognostic model. J. Clin. Oncol.24(36), 5711–5715 (2006).
   PubMed Web of Science ®Google Scholar
• Nelson DF, Martz KL, Bonner H et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology group (RTOG): RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys.23(1), 9–17 (1992).
   PubMed Web of Science ®Google Scholar
• O’Neill BP, Dinapoli RP, Kurtin PJ, Habermann TM. Occult systemic non-Hodgkin’s lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough? J. Neurooncol.25(1), 67–71 (1995).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Zoldan MC, Terreni MR, Villa E. Importance of complete staging in non-Hodgkin’s lymphoma presenting as a cerebral mass lesion. Cancer77(5), 827–833 (1996).
   PubMed Web of Science ®Google Scholar
• Jahnke K, Hummel M, Korfel A et al. Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J. Clin. Oncol.24(29), 4754–4757 (2006).
   PubMed Web of Science ®Google Scholar
• Bollen EL, Brouwer RE, Hamers S et al. Central nervous system relapse in non-Hodgkin’s lymphoma: a single-center study of 532 patients. Arch. Neurol.54(7), 854–859 (1997).
   PubMed Web of Science ®Google Scholar
• Levitt LJ, Dawson DM, Rosenthal DS, Moloney WC. CNS involvement in the non-Hodgkin’s lymphomas. Cancer45(3), 545–552 (1980).
   PubMed Web of Science ®Google Scholar
• Litam JP, Cabanillas F, Smith TL, Bodey GP, Freireich EJ. Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis. Blood54(6), 1249–1257 (1979).
   PubMed Web of Science ®Google Scholar
• MacKintosh FR, Colby TV, Podolsky WJ et al. Central nervous system involvement in non-Hodgkin’s lymphoma: an analysis of 105 cases. Cancer49(3), 586–595 (1982).
   PubMed Web of Science ®Google Scholar
• van Besien K, Ha CS, Murphy S et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood91(4), 1178–1184 (1988).
   Google Scholar
• Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann. Oncol.13(7), 1099–1107 (2002).
   PubMed Web of Science ®Google Scholar
• Boehme V, Zeynalova S, Kloess M et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma – a survey of 1693 patients treated in protocols of the German high-grade non-Hodgkin’s lymphoma study group (DSHNHL). Ann. Oncol.18(1), 149–157 (2007).
   PubMed Web of Science ®Google Scholar
• Zucca E, Conconi A, Mughal TI et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the international extranodal lymphoma study group. J. Clin. Oncol.21(1), 20–27 (2003).
   PubMed Web of Science ®Google Scholar
• Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM. Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk. Lymphoma46(12), 1721–1727 (2005).
   PubMed Web of Science ®Google Scholar
• Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev.20(6), 319–332 (2006).
   PubMed Web of Science ®Google Scholar
• Bos GM, van Putten WL, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek A. For which patients with aggressive non-Hodgkin’s lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann. Oncol.9(2), 191–194 (1998).
   PubMed Web of Science ®Google Scholar
• Ersbøll J, Schultz HB, Thomsen BL, Keiding N, Nissen NI. Meningeal involvement in non-Hodgkin’s lymphoma: symptoms, incidence, risk factors and treatment. Scand. J. Haematol.35(5), 487–496 (1985).
   PubMedGoogle Scholar
• Johnson GJ, Oken MM, Anderson JR, O’Connell MJ, Glick JH. Central nervous system relapse in unfavourable-histology non-Hodgkin’s lymphoma: is prophylaxis indicated? Lancet2(8404), 685–687 (1984).
   PubMed Web of Science ®Google Scholar
• Recht L, Straus DJ, Cirrincione C, Thaler HT, Posner JB. Central nervous system metastases from non-Hodgkin’s lymphoma: treatment and prophylaxis. Am. J. Med.84(3 Pt 1), 425–435 (1988).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Kormanik PA. Non-AIDS-related lymphomatous meningitis: combined modality therapy. Neurology49(6), 1728–1731 (1997).
   PubMed Web of Science ®Google Scholar
• van Besien K, Forman A, Champlin R. Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann. Oncol.8(6), 515–524 (1997).
   PubMed Web of Science ®Google Scholar
• Hollender A, Kvaloy S, Lote K, Nome O, Holte H. Prognostic factors in 140 adult patients with non-Hodgkin’s lymphoma with systemic central nervous system (CNS) involvement: a single centre analysis. Eur. J. Cancer36(14), 1762–1768 (2000).
   PubMed Web of Science ®Google Scholar
• Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J. Neurooncol.38(2–3), 151–157 (1998).
   PubMed Web of Science ®Google Scholar
• Bokstein F, Lossos A, Lossos IS, Siegal T. Central nervous system relapse of systemic non-Hodgkin’s lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk. Lymphoma43(3), 587–593 (2002).
   PubMed Web of Science ®Google Scholar
• Schultz C, Scott C, Sherman W et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J. Clin. Oncol.14(2), 556–564 (1996).
   PubMed Web of Science ®Google Scholar
• O’Neill BP, Wang CH, O’Fallon JR et al. Primary central nervous system non-Hodgkin’s lymphoma (PCNSL): survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment group (NCCTG) study 86–72–52. Int. J. Radiat. Oncol. Biol. Phys.43(3), 559–563 (1999).
   PubMed Web of Science ®Google Scholar
• Mead GM, Bleehen NM, Gregor A et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin’s lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer89(6), 1359–1370 (2000).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Yahalom J, Heinemann MH, Cirrincione C, Thaler HT, Krol G. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology40(1), 80–86 (1990).
   PubMed Web of Science ®Google Scholar
• Hunt MA, Jahnke K, Murillo TP, Neuwelt EA. Distinguishing primary central nervous system lymphoma from other central nervous system diseases: a neurosurgical perspective on diagnostic dilemmas and approaches. Neurosurg. Focus21(5), E3 (2006).
   Google Scholar
• Herrlinger U, Schabet M, Eichhorn M et al. Prolonged corticosteroid induced remission in primary central nervous system lymphoma: report of a case and review of the literature. Eur. Neurol.36(4), 241–243 (1996).
   PubMed Web of Science ®Google Scholar
• Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J. Neurooncol.43(3), 241–247 (1999).
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Müller F, Feuerhake F, Schäfer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica93(1), 147–148 (2008).
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Marks R, Müller F et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and Phase II study. Ann. Oncol.20(2), 319–325 (2009).
   PubMed Web of Science ®Google Scholar
• Thyss A, Milano G, Deville A, Manassero J, Renee N, Schneider M. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies. Eur. J. Cancer Clin. Oncol.23(6), 843–847 (1987).
   PubMedGoogle Scholar
• Milano G, Thyss A, Serre Debeauvais F et al. CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m2 methotrexate. A study from the EORTC Children’s Leukemia Cooperative Group. Eur. J. Cancer26(4), 492–495 (1990).
   PubMed Web of Science ®Google Scholar
• Millot F, Rubie H, Mazingue F, Mechinaud F, Thyss A. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate. Leuk. Lymphoma14(1–2), 141–144 (1994).
   PubMed Web of Science ®Google Scholar
• Jahnke K, Korfel A, Martus P et al.; German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG). High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann. Oncol.16(3), 445–449 (2005).
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Schabet M, Brugger W et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann. Neurol.51(2), 247–252 (2002).
   PubMed Web of Science ®Google Scholar
• Batchelor T, Carson K, O’Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J. Clin. Oncol.21(6), 1044–1049 (2003).
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Küker W, Uhl M et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann. Neurol.57(6), 843–847 (2005).
   PubMed Web of Science ®Google Scholar
• Pels H, Schmidt-Wolf IG, Glasmacher A et al. Primary central nervous system lymphoma: results of a pilot and Phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J. Clin. Oncol.21(24), 4489–4495 (2003).
   PubMed Web of Science ®Google Scholar
• Korfel A, Martus P, Nowrousian MR et al.; German primary central nervous system lymphoma Study Group (G-PCNSL-SG). Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma. Br. J. Haematol.128(2), 177–183 (2005).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ; Radiation Therapy Oncology Group Study 93–10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J. Clin. Oncol.20(24), 4643–4648 (2002).
   PubMed Web of Science ®Google Scholar
• Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J. Clin. Oncol.16(3), 859–863 (1998).
   PubMed Web of Science ®Google Scholar
• Blay JY, Conroy T, Chevreau C et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurological toxicity in a retrospective series. J. Clin. Oncol.16(3), 864–871 (1998).
   PubMed Web of Science ®Google Scholar
• Poortmans PM, Kluin-Nelemans HX, Haaxma-Reiche H et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J. Clin. Oncol.21(24), 4483–4488 (2003).
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Taillandier L, Chinot O et al.; European Organization for Research and Treatment of Cancer Brain Tumor Group. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter Phase II study (26952) of the European organization for Research and Treatment of Cancer Brain Tumor group. J. Clin. Oncol.21(14), 2726–2731 (2003).
   PubMed Web of Science ®Google Scholar
• Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J. Neurooncol.85(2), 207–211 (2007).
   PubMed Web of Science ®Google Scholar
• McAllister LD, Doolittle ND, Guastadisegni PE et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery46(1), 51–60 (2000).
   PubMed Web of Science ®Google Scholar
• Angelov L, Doolittle ND, Kraemer DF et al. Blood–brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J. Clin. Oncol.27(21), 3503–3509 (2009).
   PubMed Web of Science ®Google Scholar
• Abrey LE, Moskowitz CH, Mason WP et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J. Clin. Oncol.21(22), 4151–4156 (2003).
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Marks R, Ihorst G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J. Clin. Oncol.24(24), 3865–3870 (2006).
   PubMed Web of Science ®Google Scholar
• Khan RB, Shi W, Thaler HT, DeAngelis LM, Abrey LE. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J. Neurooncol.58(2), 175–178 (2002).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Abrey LE, Blay JY et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12–15, 2002. J. Clin. Oncol.21(12), 2407–2414 (2003).
   PubMed Web of Science ®Google Scholar
• Hryniuk WM, Bertino JP. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical–biochemical correlates. J. Clin. Invest.48(11), 2140–2155 (1969).
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N. Engl. J. Med.293(4), 161–166 (1975).
   PubMed Web of Science ®Google Scholar
• Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J. Pharmacol. Exp. Ther.195(1), 73–83 (1975).
   PubMed Web of Science ®Google Scholar
• Kimelberg HK, Kung D, Watson RE, Reiss FL, Biddlecome SM, Bourke RS. Direct administration of methotrexate into the central nervous system of primates: distribution and degradation of methotrexate in nervous and systemic tissue after intraventricular injection. J. Neurosurg.48(6), 883–894 (1978).
   PubMed Web of Science ®Google Scholar
• Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat. Rep.65(Suppl. 1), 89–98 (1981).
   PubMedGoogle Scholar
• Ferreri AJ, Reni M, Pasini F et al. A multicenter study of treatment of primary CNS lymphoma. Neurology58(10), 1513–1520 (2002).
   PubMed Web of Science ®Google Scholar
• Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J. Neurosurg.81(2), 188–195 (1994).
   PubMed Web of Science ®Google Scholar
• Glass J, Shustik C, Hochberg FH, Cher L, Gruber ML. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J. Neurooncol.30(3), 257–265 (1996).
   PubMed Web of Science ®Google Scholar
• Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology46(6), 1757–1759 (1996).
   PubMed Web of Science ®Google Scholar
• Pels H, Juergens A, Glasmacher A et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a Phase II study. J. Neurooncol.91(3), 299–305 (2009).
   PubMed Web of Science ®Google Scholar
• Shah GD, Yahalom J, Correa DD et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J. Clin. Oncol.25(30), 4730–4735 (2007).
   PubMed Web of Science ®Google Scholar
• Raviola G. The structural basis of the blood–ocular barriers. Exp. Eye Res.25(Suppl.), 27–63 (1977).
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J. The blood–ocular barriers. Surv. Ophthalmol.23(5), 279–296 (1979).
   PubMed Web of Science ®Google Scholar
• Margolis L, Fraser R, Lichter A, Char DH. The role of radiation therapy in the management of ocular reticulum cell sarcoma. Cancer45(4), 688–692 (1980).
   PubMed Web of Science ®Google Scholar
• Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann. Intern. Med.119(11), 1093–1104 (1993).
   PubMed Web of Science ®Google Scholar
• Buggage RR, Chan CC, Nussenblatt RB. Ocular manifestations of central nervous system lymphoma. Curr. Opin. Oncol.13(3), 137–142 (2001).
   PubMed Web of Science ®Google Scholar
• Char DH, Ljung BM, Miller T, Phillips T. Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology95(5), 625–630 (1988).
   PubMed Web of Science ®Google Scholar
• Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch. Ophthalmol.115(9), 1152–1156 (1997).
   PubMed Web of Science ®Google Scholar
• Smith JR, Rosenbaum JT, Wilson DJ et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology109(9), 1709–1716 (2002).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW. High-dose methotrexate for intraocular lymphoma. Clin. Cancer Res.9(2), 711–715 (2003).
   PubMed Web of Science ®Google Scholar
• Jahnke K, Wagner T, Bechrakis NE et al. Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma. Ann. Oncol.16(12), 1974–1978 (2005).
   PubMed Web of Science ®Google Scholar
• Jahnke K, Thiel E, Bechrakis NE et al. Ifosfamide or trofosfamide in patients with intraocular lymphoma. J. Neurooncol.93(2), 213–217 (2009).
   PubMed Web of Science ®Google Scholar
• Soussain C, Suzan F, Hoang-Xuan K et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J. Clin. Oncol.19(3), 742–749 (2001).
   PubMed Web of Science ®Google Scholar
• Soussain C, Hoang-Xuan K, Taillandier L et al.; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J. Clin. Oncol.26(15), 2512–2518 (2008).
   PubMed Web of Science ®Google Scholar
• Jahnke K, Korfel A, O’Neill BP et al. International study on low-grade primary central nervous system lymphoma. Ann. Neurol.59(5), 755–762 (2006).
   PubMed Web of Science ®Google Scholar
• Reni M, Ferreri AJ. Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann. Hematol.80(Suppl. 3), B113–B117 (2001).
   Google Scholar
• Soussain C, Merle-Béral H, Reux I et al. A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases. Leuk. Lymphoma23(3–4), 339–345 (1996).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM. Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. J. Neurooncol.43(3), 249–257 (1999).
   PubMed Web of Science ®Google Scholar
• Reni M, Ferreri AJ, Villa E. Second-line treatment for primary central nervous system lymphoma. Br. J. Cancer79(3–4), 530–534 (1999).
   PubMed Web of Science ®Google Scholar
• Jahnke K, Thiel E, Martus P et al. German primary central nervous system lymphoma study group: relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J. Neurooncol.80(2), 159–165 (2006).
   PubMed Web of Science ®Google Scholar
• Plotkin SR, Betensky RA, Hochberg FH et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin. Cancer Res.10(17), 5643–5646 (2004).
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J. Clin. Oncol.23(7), 1507–1513 (2005).
   PubMed Web of Science ®Google Scholar
• Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology69(11), 1178–1182 (2007).
   PubMed Web of Science ®Google Scholar
• Reni M, Zaja F, Mason W et al. Temozolomide as salvage treatment in primary brain lymphomas. Br. J. Cancer96(6), 864–867 (2007).
   PubMed Web of Science ®Google Scholar
• Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of temozolomide and rituximab. Neurology63(5), 901–903 (2004).
   PubMed Web of Science ®Google Scholar
• Fischer L, Thiel E, Klasen HA et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann. Oncol.17(7), 1141–1145 (2006).
   PubMed Web of Science ®Google Scholar
• Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J. Neurooncol.86(2), 211–215 (2008).
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Witzig TE. Radioimmunotherapy for B-cell non-Hodgkin’s lymphoma. Clin. Adv. Hematol. Oncol.4(3), 225–231 (2006).
   PubMedGoogle Scholar
• Doolittle ND, Jahnke K, Belanger R et al. Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk. Lymphoma48(9), 1712–1720 (2007).
   PubMed Web of Science ®Google Scholar
• Maza S, Kiewe P, Munz DL et al. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin™) in primary CNS lymphoma. Neuro. Oncol.11(4), 423–429 (2009).
   PubMed Web of Science ®Google Scholar
• Iwamoto FM, Schwartz J, Pandit-Taskar N et al. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer110(11), 2528–2534 (2007).
   PubMed Web of Science ®Google Scholar
• Colocci N, Glantz M, Recht L. Prevention and treatment of central nervous system involvement by non-Hodgkin’s lymphoma: a review of the literature. Semin. Neurol.24(4), 395–404 (2004).
   PubMed Web of Science ®Google Scholar
• van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk. Lymphoma49(Suppl. 1), 52–58 (2008).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Kormanik PA. Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology46(6), 1674–1677 (1996).
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Cole BF, Recht L et al. High-dose intravenous methotrexate for patients with nonleukemic cancer: is intrathecal chemotherapy necessary? J. Clin. Oncol.16(4), 1561–1567 (1998).
   PubMed Web of Science ®Google Scholar
• Williams CD, Pearce R, Taghipour G, Green ES, Philip T, Goldstone AH. Autologous bone marrow transplantation for patients with non-Hodgkin’s lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome – a report by the European Bone Marrow Transplant Lymphoma registry. J. Clin. Oncol.12(11), 2415–2422 (1994).
   PubMed Web of Science ®Google Scholar
• Alvarnas JC, Negrin RS, Horning SJ et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin’s lymphoma. Biol. Blood Marrow Transplant.6(3A), 352–358 (2000).
   PubMed Web of Science ®Google Scholar
• Jahnke K, Thiel E, Martus P, Schwartz S, Korfel A. Retrospective study of prognostic factors in non-Hodgkin’s lymphoma secondarily involving the central nervous system. Ann. Hematol.85(1), 45–50 (2006).
   PubMed Web of Science ®Google Scholar
• Doolittle ND, Abrey LE, Shenkier TN et al. Brain parenchyma involvement as isolated central nervous system (CNS) relapse of systemic non-Hodgkin’s lymphoma: an international primary CNS lymphoma collaborative group report. Blood111(3), 1085–1093 (2008).
   PubMed Web of Science ®Google Scholar
• Jahnke K, Muldoon LL, Varallyay CG et al. Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma. Neuro. Oncol. DOI: 15228517-2008-119v2 (2009) (Epub ahead of print).
   Google Scholar
• Chan CC, Fischette M, Shen D Mahesh SP, Nussenblatt RB, Hochman J. Murine model of primary intraocular lymphoma. Invest. Ophthalmol. Vis. Sci.46(2), 415–419 (2005).
   PubMed Web of Science ®Google Scholar
• Li Z, Mahesh SP, Shen de F et al. Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma. Cancer Res.66(21), 10586–10593 (2006).
   PubMed Web of Science ®Google Scholar
• Grimm SA, Pulido JS, Jahnke K et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma collaborative group report. Ann. Oncol.18(11), 1851–1855 (2007).
   PubMed Web of Science ®Google Scholar
• Grimm SA, McCannel CA, Omuro AM et al. Primary CNS lymphoma with intraocular involvement: international PCNSL collaborative group report. Neurology71(17), 1355–1360 (2008).
   PubMed Web of Science ®Google Scholar
• Kitzmann AS, Pulido JS, Mohney BG et al. Intraocular use of rituximab. Eye21(12), 1524–1527 (2007).
   PubMed Web of Science ®Google Scholar
• Sandor V, Stark-Vancs V, Pearson D et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J. Clin. Oncol.16(9), 3000–3006 (1998).
   PubMed Web of Science ®Google Scholar
• Brada M, Hjiyiannakis D, Hines F, Traish D, Ashley S. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int. J. Radiat. Oncol. Biol. Phys.40(5), 1157–1162 (1998).
   PubMed Web of Science ®Google Scholar